USE OF HOMOHARRINGTONINE IN PREPARATION OF HUMAN BODY BETA-CORONAVIRUS REPLICATION INHIBITOR

• Main Authors: WEN, Haijun, WU, ChungI
• Format: Patent
• Language: Chinese; English; French
• Published: 07.10.2021
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

Provided are the use of homoharringtonine (HHT) in the preparation of a drug for resisting beta-coronavirus infections and a human body beta-coronavirus replication inhibitor, and a preparation and method for treating diseases caused by beta-coronavirus. Research reveals for the first time that HHT not only has a good inhibition effect on the first step of protein synthesis, but also unexpectedly has an inhibition effect on each step extended from the protein synthesis and can better inhibit the synthesis of long-acting proteins. Beta-coronaviruses including HCoV-HKU1, HCoV-OC43, SARS-CoV, MERS-CoV, SARS-CoV-2, etc., have longer ORFs and are more sensitive to HHT, so that HHT has a better replication inhibition effect on the beta-coronaviruses, and furthermore, a feasible solution is provided for controlling the replication of coronaviruses. The effect of HHT on treating diseases caused by beta-coronaviruses (including SARS-CoV-2) is verified for the first time by means of carrying out cell experiments and us